Antifungal agents in hematopoietic stem cell transplantation

Current Pharmaceutical Design

Volumn 14, Issue 20, 2008, Pages 2011-2021

  Parameswaran, G Iyer ^a   Segal, Brahm H ^b   Almyroudis, Nikolaos G ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aspergillus; Candida; Fusarium; Mold; Stem cell transplantation; Yeast; Zygomycetes

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA GLUCAN; CASPOFUNGIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFEROXAMINE; ECHINOCANDIN; ELECTROLYTE; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; GALACTOMANNAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POSACONAZOLE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANDIDEMIA; CLINICAL TRIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEVER; FUSARIUM; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GRANULOCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; RECOMMENDED DRUG DOSE; REVIEW; SCEDOSPORIUM; UNSPECIFIED SIDE EFFECT; ZYGOMYCETES;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; MYCOSES; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 52949089664     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785061391     Document Type: Review

References (115)

1. Baddley JW, Stroud TP, Salzman D and Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
2. Marr KA, Carter RA, Boeckh M, Martin P and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
3. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-9.
4. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-8.
5. McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17: 397-404.
6. Marr KA, Carter RA, Crippa F, Wald A and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
7. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
8. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
9. Lin SJ, Schranz J and Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
10. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 Suppl 1: S49-58.
11. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
12. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D and Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
13. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
14. Marr KA, Seidel K, White TC and Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
15. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
16. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
17. van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-54.
18. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
19. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
20. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
21. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
22. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
23. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
24. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis-has the principle been proven? N Engl J Med 2007; 356: 409-11.
25. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
26. Pizzo PA, Robichaud KJ, Gill FA and Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
27. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86: 668-72.
28. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
29. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
30. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-22.
31. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
32. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003; 4: 974-90.
33. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
34. Maertens J, Verhaegen J, Lagrou K, Van Eldere J and Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-10.
35. Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-65.
36. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immuno-compromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
37. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-906.
38. Pfeiffer CD, Fine JP and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006; 42: 1417-27.
39. Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B and Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007; 110: 830-4.
40. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B and Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
41. Mattei D, Rapezzi D, Mordini N, Cuda F, Lo Nigro C, Musso M, et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004; 42: 5362-3.
42. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711-27, viii.
43. Marr KA, Laverdiere M, Gugel A and Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
44. Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005; 41: 1143-9.
45. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
46. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
47. White PL, Linton CJ, Perry MD, Johnson EM and Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-86.
48. Florent M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie JP, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006; 193: 741-7.
49. Kami M, Fukui T, Ogawa S, Kazuyama Y, Machida U, Tanaka Y, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504-12.
50. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still a ways to go. Clin Infect Dis 2006; 42: 487-9.
51. Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000; 13: 615-620.
52. White TC, Marr KA and Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
53. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
54. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
55. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
56. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996; 101: 170-6.
57. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
58. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
59. nPappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
60. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
61. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ and Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: Results from a global antifungal surveillance program. J Clin Microbiol 2008; 46: 551-9.
62. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
63. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
64. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33: 690-9.
65. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-8.
66. Barber GR, Brown AE, Kiehn TE, Edwards FF and Armstrong D. Catheter-related Malassezia furfur fungemia in immunocompromised patients. Am J Med 1993; 95: 365-70.
67. Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant 2000; 26: 645-8.
68. Gupta AK, Kohli Y, Li A, Faergemann J and Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000; 142: 758-65.
69. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, et al. Trichosporonosis in a tertiary care cancer center: Risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004; 36: 564-9.
70. Walsh TJ, Newman KR, Moody M, Wharton RC and Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986; 65: 268-79.
71. Erer B, Galimberti M, Lucarelli G, Giardini C, Polchi P, Baronciani D, et al. Trichosporon beigelii: A life-threatening pathogen in immunocompromised hosts. Bone Marrow Transplant 2000; 25: 745-9.
72. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
73. Uchida K, Nishiyama Y, Yokota N and Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53: 1175-81.
74. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
75. Warris A, Voss A, Abrahamsen TG and Verweij PE. Contamination of hospital water with Aspergillus fumigatus and other molds. Clin Infect Dis 2002; 34: 1159-60.
76. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-60.
77. Wald A, Leisenring W, van Burik JA and Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
78. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56 Suppl 1: I5-i11.
79. . Clin Infect Dis 2003; 37: 415-25.
80. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
81. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
82. Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, et al. Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8.
83. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
84. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
85. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
86. Zmeili OS, Soubani AO. Pulmonary aspergillosis: A clinical update. Qjm 2007; 100: 317-34.
87. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5.
88. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
89. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
90. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
91. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
92. Marr KA, Boeckh M, Carter RA, Kim HW and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
93. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
94. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
95. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-62.
96. Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections. Clin Infect Dis 1998; 26: 1290-4.
97. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 1997; 11: 1621-30.
98. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
99. Ribes JA, Vanover-Sams CL and Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
100. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
101. Sugar AM. Mucormycosis. Clin Infect Dis 1992; 14(Suppl 1): S126-9.
102. van Burik JA, Hare RS, Solomon HF, Corrado ML and Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006; 42: E61-5.
103. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
104. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
105. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-42.
106. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
107. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
108. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
109. Kontoyiannis DP, Bodey GP, Hanna H, Hachem R, Boktour M, Girgaway E, et al. Outcome determinants of fusariosis in a tertiary care cancer center: The impact of neutrophil recovery. Leuk Lymphoma 2004; 45: 139-41.
110. Tadros TS, Workowski KA, Siegel RJ, Hunter S and Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): An emerging mycosis. Hum Pathol 1998; 29: 1266-72.
111. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E and Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl 1: 48-66.
112. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad, II and Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43: 1580-4.
113. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P, et al. A randomized, blinded, multicenter trial of lipidassociated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-13.
114. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 2005; 309: 2185-9.
115. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: A hypothesis. Clin Infect Dis 2007; 44: 1089-90.